International Stem Cell Corp., a California-based biotechnology company focused on therapeutic and research products, today applauded Sir John Gurdon and Dr. Shinya Yamanaka for securing the Nobel Prize in Physiology or Medicine. The team's use of cellular reprogramming to create pluripotent stem cells has led to the development of induced pluripotent stem cells (iPS), which is now a major area of research. However, cellular reprogramming is currently accomplished by inserting genetic material, via a virus or otherwise, which raises serious safety concerns when developing treatments.
ISCO, in comparison, has developed a technology that could enable the creation of a new generation of iPS cells without these safety concerns. Unlike methods requiring the use of viruses or DNA constructs that may integrate into the genome, ISCO's new method utilizes only proteins which are naturally eliminated once they have served their purpose.
"Overall, our new technology represents a level of control that is much finer than the multiple infections necessary for viral-based systems which cannot be turned off and where the dosage level cannot be modulated," stated Dr. Ruslan Semechkin, Vice President and head of ISCO's Research and Development. "Moreover, ISCO's method can be used not only to reprogram somatic cells to become stem cells, but also transform stem cells into somatic cells. This technology provides an alternative to the existing cellular reprogramming methods and represents an enormous opportunity for ISCO to become a leader in the iPS field."
For additional information on ISCO, visit InternationalStemCell.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net